In 2016, Isomerase was approached a major pharma company looking to access an unusual cytotoxic natural product from a bacterial strain to enable preclinical testing. We were able to track down and access the strain from an external culture collection, generate an in-house fermentation procedure and complete a short strain and process improvement program. We were rapidly able to provide the client with the strain, lab procedures, and a few mgs of product for testing.
Following successful testing by the client, they returned to Isomerase for a further round of process improvement and scale-up to supply 0.5g of product for the next phase of testing.
If you would like to discuss further details about our ability to access rare strains and produce difficult to source natural products for testing, please contact us.